DRAIN TREATMENT

المعلومات الرئيسية

  • اسم تجاري:
  • DRAIN TREATMENT
  • يسخدم من اجل:
  • البشر
  • نوع الدواء:
  • الجهاز الطبي

المستندات

  • لعامة الناس:
  • النشرة المعلومات عن هذا المنتج غير متوفر حاليا، يمكنك إرسال طلب لخدمة العملاء لدينا، ونحن سوف يخطر لك في أقرب وقت ونحن قادرون على الحصول عليه.


    طلب نشرة المعلومات لعامة الناس.

الأقلمة

  • متاح في:
  • DRAIN TREATMENT
    كازاخستان
  • اللغة:
  • العربية

معلومات أخرى

الحالة

  • المصدر:
  • Ecolab
  • تخويل:
  • 924913-08
  • اخر تحديث:
  • 12-03-2018

ملخص خصائص المنتج

924913-08

1 / 6

Kay Chemical Company

8300 Capital Drive

Greensboro, North Carolina USA 27409

1-800-529-5458

1-877-231-2615 (USA/Canada), 952-853-1713 (outside USA)

28.03.2017

GHS

:

:

:

(%)

Propylene glycol

57-55-6

1 - 5

924913-08

2 / 6

0 °C

50 °C

Propylene glycol

57-55-6

TWA OEL-RL

10 mg/m3

TWA OEL-RL

150 ppm

470 mg/m3

924913-08

3 / 6

100 %

924913-08

4 / 6

924913-08

5 / 6

Propylene glycol

22,000 mg/kg :

Propylene glycol

4 h :

LC50

158.5 mg/l :

Propylene glycol

96 h :

LC50

> 10,000 mg/l :

Propylene glycol

48 h :

EC50

18,340 mg/l :

Propylene glycol

96 h :

EC50

19,000 mg/l :

924913-08

6 / 6

(ADR/ADN/RID)

)

IMDG/

(

28.03.2017

Regulatory Affairs

  • النشرة المعلومات عن هذا المنتج غير متوفر حاليا، يمكنك إرسال طلب لخدمة العملاء لدينا، ونحن سوف يخطر لك في أقرب وقت ونحن قادرون على الحصول عليه.

    طلب نشرة المعلومات لعامة الناس.



  • وثائق في اللغات الأخرى المتاحة هنا

13-7-2018

FDA approves the first drug with an indication for treatment of smallpox

FDA approves the first drug with an indication for treatment of smallpox

FDA today approved TPOXX (tecovirimat), the first drug with an indication for treatment of smallpox.

FDA - U.S. Food and Drug Administration

13-7-2018

Scientific guideline:  Guideline on good pharmacogenomic practice - First version, adopted

Scientific guideline: Guideline on good pharmacogenomic practice - First version, adopted

This guideline provides recommendations for the conduct of genomic studies in relation to medical therapy in order to provide high quality information on the impact of genomic variability on drug response. Primary focus is on the analysis of genomic germline DNA. The analysis of somatic DNA and genomic biomarkers for cancer treatment is not being discussed and might be developed as an Annex or in separate guidance.

Europe - EFSA - European Food Safety Authority EFSA Journal

9-7-2018

Statement by FDA Commissioner Scott Gottlieb, M.D., on balancing access to appropriate treatment for patients with chronic and end-of-life pain with need to take steps to stem misuse and abuse of opioids

Statement by FDA Commissioner Scott Gottlieb, M.D., on balancing access to appropriate treatment for patients with chronic and end-of-life pain with need to take steps to stem misuse and abuse of opioids

FDA Commissioner statement on balancing access to appropriate treatment for patients with chronic and end-of-life pain with need to take steps to stem opioid misuse and abuse.

FDA - U.S. Food and Drug Administration

29-6-2018

Orphan designation:  Rufinamide,  for the: Treatment of Lennox-Gastaut syndrome

Orphan designation: Rufinamide, for the: Treatment of Lennox-Gastaut syndrome

Europe - EMA - European Medicines Agency

14-6-2018

FDA approves first generic versions of Suboxone sublingual film, which may increase access to treatment for opioid dependence

FDA approves first generic versions of Suboxone sublingual film, which may increase access to treatment for opioid dependence

: FDA approved the first generic versions of Suboxone (buprenorphine and naloxone) sublingual film (applied under the tongue) for the treatment of opioid dependence.

FDA - U.S. Food and Drug Administration

13-6-2018

Orphan designation:  Ivosidenib,  for the: Treatment of acute myeloid leukaemia

Orphan designation: Ivosidenib, for the: Treatment of acute myeloid leukaemia

Europe - EMA - European Medicines Agency

8-6-2018

Orphan designation:  Mepolizumab,  for the: Treatment of Churg-Strauss syndrome

Orphan designation: Mepolizumab, for the: Treatment of Churg-Strauss syndrome

On 12 March 2013, orphan designation (EU/3/13/1116) was granted by the European Commission to Glaxo Group Ltd, United Kingdom, for mepolizumab for the treatment of Churg-Strauss syndrome.

Europe - EMA - European Medicines Agency

4-6-2018

FDA approves first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment

FDA approves first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment

FDA approves Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to decrease the chance of infection as suggested by febrile neutropenia in patients with non-myeloid cancer.

FDA - U.S. Food and Drug Administration

4-6-2018

Medical Devices that Treat Obesity: What to Know

Medical Devices that Treat Obesity: What to Know

Obesity has been linked to many health problems, including heart disease, diabetes, and high blood pressure. Treatments for obesity range from healthy eating and exercise to prescription medicine and surgery. In recent years, FDA-regulated medical devices have also played a treatment role. Learn about approved products.

FDA - U.S. Food and Drug Administration

1-6-2018

SunMed Holdings, LLC Issues a Nationwide Recall of STAT-Check and Medline Manual Resuscitator Bags

SunMed Holdings, LLC Issues a Nationwide Recall of STAT-Check and Medline Manual Resuscitator Bags

On May 29, 2018, SunMed Holdings, LLC initiated a nationwide recall of 18,808 units of STAT-Check and Medline resuscitator bags which were distributed between February 1, 2018 to May 13, 2018. The patient port retaining ring of the affected bags may not fully seat which may allow the patient port to detach during use. If this takes place, the resuscitator bags may not deliver air to the patient and result in a delay in treatment and life-threatening health consequences. There have been no reported injuri...

FDA - U.S. Food and Drug Administration

31-5-2018

Orphan designation:  Rucaparib,  for the: Treatment of ovarian cancer

Orphan designation: Rucaparib, for the: Treatment of ovarian cancer

Europe - EMA - European Medicines Agency

30-5-2018

FDA approves new treatment for moderately to severely active ulcerative colitis

FDA approves new treatment for moderately to severely active ulcerative colitis

FDA today expanded the approval of Xeljanz (tofacitinib) to include adults with moderately to severely active ulcerative colitis.

FDA - U.S. Food and Drug Administration

29-5-2018

Orphan designation:  Nilotinib,  for the: Treatment of chronic myeloid leukaemia

Orphan designation: Nilotinib, for the: Treatment of chronic myeloid leukaemia

Europe - EMA - European Medicines Agency

29-5-2018

Orphan designation:  Veliparib,  for the: Treatment of ovarian cancer

Orphan designation: Veliparib, for the: Treatment of ovarian cancer

Europe - EMA - European Medicines Agency

29-5-2018

Orphan designation:  Pasireotide,  for the: Treatment of Cushing’s disease

Orphan designation: Pasireotide, for the: Treatment of Cushing’s disease

Europe - EMA - European Medicines Agency

29-5-2018

Orphan designation:  Pasireotide,  for the: Treatment of acromegaly

Orphan designation: Pasireotide, for the: Treatment of acromegaly

Europe - EMA - European Medicines Agency

29-5-2018

Orphan designation:  Panobinostat,  for the: Treatment of multiple myeloma

Orphan designation: Panobinostat, for the: Treatment of multiple myeloma

Europe - EMA - European Medicines Agency

29-5-2018

Orphan designation:  Osilodrostat,  for the: Treatment of Cushing's syndrome

Orphan designation: Osilodrostat, for the: Treatment of Cushing's syndrome

Europe - EMA - European Medicines Agency

29-5-2018

Orphan designation:  Midostaurin,  for the: Treatment of mastocytosis

Orphan designation: Midostaurin, for the: Treatment of mastocytosis

Europe - EMA - European Medicines Agency

29-5-2018

Orphan designation:  Midostaurin,  for the: Treatment of acute myeloid leukaemia

Orphan designation: Midostaurin, for the: Treatment of acute myeloid leukaemia

Europe - EMA - European Medicines Agency

9-7-2018

Scientific guideline:  Concept paper on the need to develop a reflection paper on development of medicinal products to prevent and treat acute kidney injury, draft: consultation open

Scientific guideline: Concept paper on the need to develop a reflection paper on development of medicinal products to prevent and treat acute kidney injury, draft: consultation open

The concept paper will include discussion of and recommendations for the requirements for evaluation and development of medicinal products for the prevention and/or treatment of acute kidney injury (AKI) and its long-term complications. Relevant topics for discussion include patient populations, endpoints, study methodology, and study duration.

Europe - EMA - European Medicines Agency

13-6-2018

Scientific guideline:  Concept paper on preparation of a revised guideline on the evaluation of medicinal products indicated for treatment of bacterial infections, draft: consultation open

Scientific guideline: Concept paper on preparation of a revised guideline on the evaluation of medicinal products indicated for treatment of bacterial infections, draft: consultation open

This concept paper proposes the development of a single guideline on the clinical evaluation of medicinal products indicated for treatment of bacterial infections. The development of this single guideline is intended to merge, revise and add to the guidance that is currently included in two separate documents as follows: guideline on the evaluation of medicinal products indicated for treatment of bacterial infections (CPMP/EWP/558/95 Rev. 2), adopted in 2011 and in force since 2012 and the addendum ...

Europe - EMA - European Medicines Agency

1-6-2018

News and press releases:  New medicine for hereditary rare disease

News and press releases: New medicine for hereditary rare disease

Tegsedi addresses unmet medical need for treatment of hereditary transthyretin amyloidosis

Europe - EMA - European Medicines Agency